Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.

× No keyword cloud information.

14 in total

1. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.

Authors: Priya Bahri
Journal: Drug Saf Date: 2010-12-01 Impact factor: 5.606

Review 2. Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.

Authors: Christine Radawski; Elaine Morrato; Kenneth Hornbuckle; Priya Bahri; Meredith Smith; Juhaeri Juhaeri; Peter Mol; Bennett Levitan; Han-Yao Huang; Paul Coplan; Hu Li
Journal: Pharmacoepidemiol Drug Saf Date: 2015-10-12 Impact factor: 2.890

3. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.

Authors: Sigrid Piening; Flora M Haaijer-Ruskamp; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606

4. Risk Communication and the Pharmaceutical Industry: what is the reality?

Authors: Brian Edwards; Sweta Chakraborty
Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606

5. Good decision making requires good communication.

Authors: Baruch Fischhoff
Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606

Review 6. Risk perception and communication in sub-Saharan Africa.

Authors: Alexander Dodoo; Bruce Hugman
Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606

7. Adverse drug reactions: when the risk becomes a reality for patients.

Authors: Anthony R Cox; Tehreem F Butt
Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606

8. Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum.

Authors: Jürgen Beckmann; Ulrich Hagemann; Priya Bahri; Andrew Bate; Ian W Boyd; Gerald J Dal Pan; Brian D Edwards; I Ralph Edwards; Kenneth Hartigan-Go; Marie Lindquist; John McEwen; Yola Moride; Sten Olsson; Shanthi N Pal; Rachida Soulaymani-Bencheikh; Marco Tuccori; Claudia P Vaca; Ian C K Wong
Journal: Drug Saf Date: 2014-10 Impact factor: 5.606

9. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors: Tehreem F Butt; Anthony R Cox; Jan R Oyebode; Robin E Ferner
Journal: Drug Saf Date: 2012-12-01 Impact factor: 5.606

10. Protecting the people?: risk communication and the chequered history and performance of bureaucracy.

Authors: Bruce Hugman
Journal: Drug Saf Date: 2012-11-01 Impact factor: 5.606

4 in total

1. An Update on ISoP Special Interest Groups (SIGs).

Authors: Deirdre McCarthy; Priya Bahri; Joanne Barnes; Jean-Christophe Delumeau; Brian Edwards; Mira Harrison-Woolrych
Journal: Drug Saf Date: 2018-01 Impact factor: 5.606

2. Enhancing medication risk communication in developing countries: a cross-sectional survey among doctors and pharmacists in Malaysia.

Authors: Rema Panickar; Zoriah Aziz; Adeeba Kamarulzaman
Journal: BMC Public Health Date: 2022-07-05 Impact factor: 4.135

3. The role and strategy of ISoP in global pharmacovigilance.

Authors: Sten Olsson; Mira Harrison-Woolrych
Journal: Int J Clin Pharm Date: 2018-08-02

4. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.

Authors: Meredith Y Smith; Andrea Russell; Priya Bahri; Peter G M Mol; Sarah Frise; Emily Freeman; Elaine H Morrato
Journal: Drug Saf Date: 2018-04 Impact factor: 5.606

4 in total